- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | Inhibrx gains as Stifel issues new Buy based on lead assets | 2 | Seeking Alpha | ||
| Mi | This Inhibrx Biosciences Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Wednesday | 3 | Benzinga.com | ||
| Di | Stifel initiates Inhibrx Biosciences stock with buy rating | 2 | Investing.com | ||
| INHIBRX BIOSCIENCES Aktie jetzt für 0€ handeln | |||||
| Di | Stifel startet Coverage für Inhibrx Biosciences mit Kaufempfehlung und hohem Kursziel | 2 | Investing.com Deutsch | ||
| 19.03. | Inhibrx Biosciences, Inc.: Inhibrx Reports Fourth Quarter and Fiscal Year 2025 Financial Results | 451 | PR Newswire | SAN DIEGO, March 19, 2026 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company") today reported financial results for the fourth... ► Artikel lesen | |
| 19.03. | Inhibrx Biosciences, Inc. - 10-K, Annual Report | 1 | SEC Filings | ||
| 19.03. | Inhibrx Biosciences, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 23.02. | Inhibrx Biosciences, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 24.12.25 | Why Inhibrx's Recent Strength May Not Be Built to Last | 2 | Benzinga.com | ||
| 17.12.25 | Inhibrx: Citizens bekräftigt "Market Perform"-Rating wegen unzureichender Daten | 11 | Investing.com Deutsch | ||
| 17.12.25 | Citizens reiterates Market Perform rating on Inhibrx Biosciences stock citing limited data disclosures | 3 | Investing.com | ||
| 17.12.25 | Inhibrx Advances INBRX-106, Ozekibart Programs, Key Milestones Expected Next Year | - | RTTNews | ||
| 16.12.25 | Inhibrx provides updates on cancer treatment clinical trials | 1 | Investing.com | ||
| 16.12.25 | Inhibrx Biosciences, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 24.11.25 | Inhibrx Biosciences auf Rekordhoch: Aktie erreicht 87,4 US-Dollar trotz Warnsignalen | 6 | Investing.com Deutsch | ||
| 14.11.25 | Inhibrx Biosciences GAAP EPS of -$2.28 | 2 | Seeking Alpha | ||
| 14.11.25 | Inhibrx Biosciences, Inc.: Inhibrx Reports Third Quarter 2025 Financial Results | 341 | PR Newswire | SAN DIEGO, Nov. 14, 2025 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company") today reported financial results for the third quarter... ► Artikel lesen | |
| 24.10.25 | Morning Market Movers: Picard Medical, Qualigen Therapeutics, Inhibrx Biosciences, MidWestOne Financial GroupSee Big Swings | 879 | AFX News | BEIJING (dpa-AFX) - At 7:45 a.m. ET on Friday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| 24.10.25 | Why Are Inhibrx Biosciences Shares Soaring 76% After Hours? | 6 | Benzinga.com | ||
| 23.10.25 | Inhibrx stock soars after positive cancer drug trial results | 12 | Investing.com |
1 2 Weiter >>
24 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 35,045 | +0,04 % | QIAGEN N.V.: Qiagen Announces Form 20-F Annual Report Filing for 2025 Results | QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today that it has filed its annual report, including its audited consolidated financial statements on Form 20-F, for the year ended... ► Artikel lesen | |
| DYNE THERAPEUTICS | 18,680 | -3,51 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Announces Initiation of Phase 3 HARMONIA Trial of Z-Basivarsen in Myotonic Dystrophy Type 1 (DM1) | - HARMONIA trial will assess multi-system efficacy, safety and tolerability of z-basivarsen in DM1 - - 48-week trial will enroll approximately 150 individuals, and first sites are now open for enrollment... ► Artikel lesen | |
| IMMUNOVANT | 24,500 | -4,48 % | IMVT Stock Falls 2.4% as Batoclimab Misses Late-Stage Study Endpoints | ||
| ENLIVEN THERAPEUTICS | 45,320 | -0,66 % | H.C. Wainwright reiterates Enliven Therapeutics stock rating on Terns deal details | ||
| ZENTALIS PHARMACEUTICALS | 6,630 | +50,17 % | Jefferies raises Zentalis stock price target on ovarian cancer trial data | ||
| VERA THERAPEUTICS | 45,000 | +9,92 % | Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| ALUMIS | 23,050 | +0,48 % | Alumis Inc.: Alumis' Envudeucitinib Delivers Early and Robust Improvements in Skin Clearance, Quality of Life and Psoriasis Symptoms in Two Phase 3 Trials, Underscoring Its Potential as a Leading Oral Therapy for Plaque Psoriasis | Envudeucitinib achieved robust PASI responses by Week 16, with significant continued improvements by Week 24 in PASI 90 (68.0%, 62.1%) and PASI 100 (41.0%, 39.5%)Quality-of-life improvements and itch... ► Artikel lesen | |
| MONTE ROSA THERAPEUTICS | 17,480 | -3,16 % | Monte Rosa Therapeutics, Inc.: Monte Rosa Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Updates | Positive interim Phase 1 data of NEK7-directed MGD MRT-8102 demonstrated profound CRP reductions in elevated CVD-risk subjects; readout of expanded part 3 CRP PoC trial (now called GFORCE-1) anticipated... ► Artikel lesen | |
| PHATHOM PHARMACEUTICALS | 12,630 | 0,00 % | Phathom Pharmaceuticals Announces Preliminary Fourth Quarter and Full Year 2025 Financial Results | FLORHAM PARK, N.J., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal... ► Artikel lesen | |
| ARCELLX | 114,83 | +0,03 % | Laufende Fusionskontrollverfahren: Gilead Sciences, Foster City, CA/USA; Erwerb sämtlicher Anteile an und Kontrolle über die Arcellx, Redwood City, CA/USA | Datum der Anmeldung:13.03.2026Aktenzeichen:B3-41/26Unternehmen:Gilead Sciences, Foster City, CA/USA; Erwerb sämtlicher Anteile an und Kontrolle über die Arcellx, Redwood City, CA/USAProduktmärkte:Hämatologie... ► Artikel lesen | |
| AMYLYX PHARMACEUTICALS | 16,360 | -5,54 % | Gubra A/S: Amylyx Pharmaceuticals Announces Nomination of AMX0318 as a Novel, Long-Acting GLP-1 Receptor Antagonist Development Candidate, Identified in Collaboration with Gubra | AMX0318 selected as development candidate after meeting key criteria, demonstrating a robust chemical stability profile, strong in vitro potency, evidence of in vivo efficacy and tolerability, high... ► Artikel lesen | |
| EVOTEC | 4,530 | +0,09 % | EQS-News: Evotec SE: Evotec nominiert Dieter Weinand als Aufsichtsratsvorsitzenden | EQS-News: Evotec SE
/ Schlagwort(e): Personalie
Evotec nominiert Dieter Weinand als Aufsichtsratsvorsitzenden
07.04.2026 / 07:30 CET/CEST
Für den Inhalt der Mitteilung... ► Artikel lesen | |
| BIONTECH | 81,40 | -0,06 % | BioNTech-Wirkstoff BNT323 zeigt Wirkung bei Gebärmutterkrebs | BioNTech hat positive Daten aus einer Phase-2-Studie mit dem Antikörper-Wirkstoff-Konjugat Trastuzumab Pamirtecan (BNT323/DB-1303) veröffentlicht. In einer Kohorte mit stark vorbehandelten Patientinnen... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 19,670 | +1,86 % | Summit Therapeutics Has Scarcity Value In A Crowded Drug Race: Analyst | ||
| CG ONCOLOGY | 67,69 | -1,25 % | H.C. Wainwright hebt Kursziel für CG Oncology auf 100 US-Dollar an |
Das Unternehmen INHIBRX BIOSCIENCES INC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von -0,47 (-0,62 %) liegt der Kurs bei 75,28 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu INHIBRX BIOSCIENCES INC finden Sie auf Wallstreet Online.